Review, Analyses and Comparisons of Interventions in Active and Completed Clinical Trials of Alzheimer’s Disease

Main Article Content

Aaryan Shah



Alzheimer’s disease is an incurable neurodegenerative disorder causing deteriorating cognitive function and memory loss. The purpose of this paper is to create a comparable landscape of completed and current clinical trials and therapeutic interventions for Alzheimer’s disease, identifying future hallmarks of neurodegenerative research. In the status quo, the urgency for new drugs and interventions surges as the aging population and cases of cognitive impairment grow. Current FDA-approved drugs have only decreased disease progression slightly; these drugs last for brief periods and are useful for symptom management rather than reversing pathogenesis. Through the data compilation, intervention analysis, and the corresponding figures that provide a visual perspective of the respective trends, this review article effectively identifies the developments and gaps for intervention in Alzheimer’s disease clinical trials. The methodology follows the specific guidelines and reporting standards of the Methodological Expectations for Cochrane Intervention Reviews (MECIR) and Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA). Moreover, inclusion and exclusion criteria were centered upon publication date, trial results, and a multitude of keyword searches pertaining to Alzheimer’s disease and cognitive impairment. Based on the review of clinical trials and literature precedent, descriptions of advancements are provided. Examples of these developments include the new interventions of stem cell therapy and declining trend of active immunotherapeutics. Trial details about the specific interventions were compiled using the ClinicalTrials.Gov database. Analysis of pending and completed trials are discussed based on advancements in Alzheimer’s disease research and the progression of drug development.